Literature DB >> 10070290

Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group.

G Gatta1, M B Lasota, A Verdecchia.   

Abstract

This study concerns the survival of European patients diagnosed between 1978 and 1989 with cancer of corpus and cervix uteri and ovary. Variations in survival in relation to age, country and period of diagnosis were examined. Data from the EUROCARE study were supplied by population-based cancer registries in 17 countries to a common protocol. Five years after diagnosis, relative survival rates were 75, 62 and 35% for cancers of the endometrium, cervix and ovary, respectively. Survival decreased markedly with age. The decrease was especially evident for ovarian cancer, which declined from 65% (15-45 years) to 18% (75+ years). In 1985-1989 there were important inter-country differences in survival for European women with gynaecological cancers: Eastern European countries were characterised by low 5-year relative survival whilst in Sweden, Austria, The Netherlands and Switzerland survival was generally higher than for other European countries. From 1978-1989, 5-year relative survival improved slightly for cervical cancer and improved more among the oldest patients. Prognosis also improved slightly for patients with ovarian tumours and this increase (around 20%) was concentrated among patients between 15 and 64 years of age. Intercountry differences in survival did not in general reduce over time, although for ovarian cancer survival differences narrowed probably in relation to the more widespread use of more effective chemotherapy. Intercountry and time differences in survival for cervical cancer are almost certainly related to variations in the effectiveness of cervical screening programmes. For corpus uteri cancer there was no improvement in survival over the period of this study and intercountry survival differences for this cancer are probably related to differences in patient management.

Entities:  

Mesh:

Year:  1998        PMID: 10070290     DOI: 10.1016/s0959-8049(98)00326-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

2.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer.

Authors:  J B Welsh; P P Zarrinkar; L M Sapinoso; S G Kern; C A Behling; B J Monk; D J Lockhart; R A Burger; G M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

3.  The planning of cervical cancer screening programmes in eastern Europe: is viral testing a suitable alternative to smear testing?

Authors:  C Sherlaw-Johnson; S Gallivan
Journal:  Health Care Manag Sci       Date:  2000-09

4.  Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma.

Authors:  Melis Gultekin; Ferah Yildiz; Gokhan Ozyigit; Havva Beyaz; Mutlu Hayran; Faruk Kose; Kunter Yuce; Ali Ayhan
Journal:  Med Oncol       Date:  2012-03-14       Impact factor: 3.064

5.  Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays.

Authors:  Michael E Hudson; Irina Pozdnyakova; Kenneth Haines; Gil Mor; Michael Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

6.  The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer.

Authors:  Takeshi Hisamatsu; Seiji Mabuchi; Tomoyuki Sasano; Hiromasa Kuroda; Ryoko Takahashi; Yuri Matsumoto; Mahiru Kawano; Katsumi Kozasa; Kei Takahashi; Kenjiro Sawada; Koji Matsuo; Yutaka Tamada; Eiichi Morii; Yasuhiko Kitadai; Tadashi Kimura
Journal:  Clin Exp Metastasis       Date:  2015-10-06       Impact factor: 5.150

7.  Titanium salan complexes displays strong antitumor properties in vitro and in vivo in mice.

Authors:  Timo A Immel; Ulrich Groth; Thomas Huhn; Peter Öhlschläger
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

8.  Survival of patients with ovarian cancer in central and northern Denmark, 1998-2009.

Authors:  Anne Fia Grann; Mette Nørgaard; Jan Blaakær; Erik Søgaard-Andersen; Jacob Bonde Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-21       Impact factor: 4.790

9.  Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage.

Authors:  Tianhui Chen; Lina Jansen; Adam Gondos; Meike Ressing; Bernd Holleczek; Alexander Katalinic; Hermann Brenner
Journal:  BMC Cancer       Date:  2012-03-30       Impact factor: 4.430

10.  Circulating soluble Fas levels and risk of ovarian cancer.

Authors:  Arslan Akhmedkhanov; Eva Lundin; Seth Guller; Annekatrin Lukanova; Andrea Micheli; Yuehong Ma; Yelena Afanasyeva; Anne Zeleniuch-Jacquotte; Vittorio Krogh; Per Lenner; Paola Muti; Sabina Rinaldi; Rudolf Kaaks; Franco Berrino; Göran Hallmans; Paolo Toniolo
Journal:  BMC Cancer       Date:  2003-12-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.